Publication Name	World Journal of Gastroenterology
Manuscript ID	33109
Country	Italy

Received	2017-02-06 16:09
Peer-Review Started	2017-02-09 09:24
To Make the First Decision	2017-03-03 09:15
Return for Revision	2017-03-03 11:09
Revised	2017-03-15 04:02
Second Decision	2017-03-28 16:48
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-03-31 08:04
Articles in Press	2017-03-31 08:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-04-17 09:28
Publish the Manuscript Online	2017-05-27 00:33

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Hepatitis C in injection drug users: It is time to treat
Manuscript Source	Invited Manuscript
All Author List	Alberto Grassi and Giorgio Ballardini
Funding Agency and Grant Number
Corresponding Author	Alberto Grassi, MD, PhD, Internal Medicine and Hepatology Division, Infermi Hospital, Viale Settembrini 2, 47921 Rimini, Italy. albgrassi@yahoo.com
Key Words	Hepatitis C; Drug users; Peg-interferon; Direct antiviral agents; Hepatitis C virus treatment
Core Tip	It is well demonstrated that injection drug users (IDUs) on maintenance treatment with methadone/buprenorphine can be treated for hepatitis C virus (HCV) with response rate, tolerability and side effects similar to those reported in non-IDUs. European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C 2016 confirm that HCV treatment for IDUs should be considered on an individualized basis and delivered within a multidisciplinary team setting; a history of intravenous drug use and recent drug use at treatment initiation are not associated with reduced sustained viral response and decisions to treat must be made on a case-by-case basis.
Publish Date	2017-05-27 00:33
Citation	Grassi A, Ballardini G. Hepatitis C in injection drug users: It is time to treat. World J Gastroenterol 2017; 23(20): 3569-3571
URL	http://www.wjgnet.com/1007-9327/full/v23/i20/3569.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i20.3569

Full Article (PDF)	WJG-23-3569.pdf
Full Article (Word)	WJG-23-3569.doc
Manuscript File	33109-Review.doc
Answering Reviewers	33109-Answering reviewers.pdf
Audio Core Tip	33109-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	33109-Conflict-of-interest statement.pdf
Copyright License Agreement	33109-Copyright assignment.pdf
Peer-review Report	33109-Peer-review(s).pdf
Scientific Misconduct Check	33109-Scientific misconduct check.pdf
Scientific Editor Work List	33109-Scientific editor work list.pdf